章毅-国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久基础医学院

国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久

博士生导师您现在的位置是: 学院首页 >> 人才建设 >>

章毅
2025-09-19 09:23:28       来源:

基础医学院研究生导师个人信息

           

姓    名

章毅

性   别

出 生 年

1971

系/教研室

药理

职    称

教授

职    务


导师类型

博导

最高学历/学位/毕业院校

博士

E-mail

Zhangduoduo2007@163.com

学科专业

药理学

研究方向

代谢性疾病发病机制及药物干预

人才称号

三晋英才科技创新领军人才,山西省学术技术带头人,山西省高等学校优秀青年学术带头人,山西省科教兴晋突出贡献专家

学术兼职

中国生物物理学会代谢生物学分会理事,山西省药学会理事,山西省药理学会理事,山西省生理学会理事,山西省医师协会药物及医疗器械临床试验专业委员会常务委员

学习工作经历

教育经历

(1) 2001.9–2004.7, 国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久, 生理学, 博士

(2) 1996.9–1999.7, 国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久, 药理学, 硕士

(3) 1989.9–1994.7, 国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久, 临床医学, 学士

科研与学术工作经历

(1)  1994-至今, 国产亚洲精品美女久久久_99久无码中文字幕一本久道_亚洲成AV人影院_亚洲AV影院一区二区三区 狠狠躁夜夜躁人人爽天天不卡_国产激情久久久久影院老熟女_精品性高朝久久久久久久,教师

(2) 2007.4-2010.7, Department of   Medicine, University of

Toronto, 博士后, 合作导师:   Herbert Gaisano

(3) 2004.11-2007.3, Department of   Physiology, University of

Toronto,   博士后, 合作导师: Michael Wheeler

主持的科研

/教学项目

1.    国家自然科学基金面上项目: Kv通道介导罗氟司特促进胰岛素分泌和抑制β细胞凋亡双重效应及其机制研究(81973378),55万,2020-2023,负责人。

2.    国家自然科学基金面上项目: AT1受体介导的胰岛素分泌特点及机制研究(81670710),55万,2017-2020,负责人。

3.    国家自然科学基金面上项目:骨钙素促胰岛素分泌的离子通道调控机制研究(81273564),45万,2013-2016,负责人。

4.    国家自然科学基金面上项目:Kv通道介导P2Y受体调控的葡萄糖依赖性促胰岛素分泌(81070662),36万,2011-2013,负责人。

5.    山西省专利转化专项计划项目:一种小分子GLP-1R激动剂及其在代谢性疾病治疗上的应用(202304016),10万,2023.4-2024.3,负责人。

6.    中央引导地方科技发展资金:靶向GLP-1R的抗糖尿病减重创新药物临床前研究(YDZJSX2022A059),40万,2022.7-2025.6,负责人。

7.    亚宝药业集团股份有限公司横向课题:YBHY012治疗小细胞肺癌小鼠模型药效学研究,12万,2020,负责人。

8.    山西省高等学校优秀成果培育项目:嘌呤(P2Y)受体激动剂促胰岛素分泌作用及机制研究(2019KJ022),5万,2019-2021,负责人。

9.    西南医科大学医学电生理学重点实验室开放基金:罗氟司特通过 KV 通道调控胰岛素分泌和细胞凋亡的作用机制研究,5万,2019-2021,负责人。

10. 亚宝药业集团股份有限公司横向课题:“降糖胶囊”糖尿病药物干预实验研究,15.9万,2019,负责人。

11. 山西省回国留学人员科研资助项目:血管紧张素Ⅱ受体调控胰岛素分泌及机制研究(2017-053),3万,   2017.7-2020.7,负责人

12. 山西省留学回国人员科技活动项目择优资助:骨钙素对胰岛功能的调控作用研究. (2016-97)5 万, 2016-2018,负责人.

13. 山西省自然科学基金:嘌呤受体激动剂促胰岛素分泌作用机制研究(2012011039-8),5万,2012-2014,负责人。

14. 山西省回国留学人员科研资助项目:P2Y受体激动剂促胰岛素分泌的机制研究(2012-046),6万,2012-2014,负责人。

15. 山西省留学人员科技活动项目择优资助:P2Y受体对胰岛素分泌作用的调控机制研究(2011-762),12万,2011-2013,负责人。

16. 山西省高等学校优秀青年学术带头人(2011-24),20万,2011-2013,负责人。

代表性成果

(论文/专利/专著等)

SCI论文:

1.Guo C, Zhang Y, Xue H, Zhao X, Wang B, Deng L, Zhu X, Zhang   X, Zhang Y, Liu Y. Butein Alleviates Non-Alcoholic Steatohepatitis in   Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway. Drug Des   Devel Ther. 2025 Aug 14;19:7015-7031. doi: 10.2147/DDDT.S530855. PMID:   40831700; PMCID: PMC12360368.

2.Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y*, Liu Y*.   The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes   Metab. 2024 Aug 14. doi: 10.1111/dom.15821. Epub ahead of print. PMID:   39140233.

3.Wu B, Li R, Hao J, Qi Y, Liu B, Wei H, Li Z, Zhang Y*, Liu   Y*. CT semi-quantitative score used as risk factor for hyponatremia in   patients with COVID-19: a cross-sectional study. Front Endocrinol (Lausanne).   2024 Jun 14;15:1342204. doi: 10.3389/fendo.2024.1342204. PMID: 38948513;   PMCID: PMC11211362.

4.Li M, Yang X, Li R, Wu B, Hao J, Qi Y, Bai T, Yang L, Zhang   Y*, Liu Y*. Visceral Fat Area and Subcutaneous Fat Area Increase in   Hyperthyroidism Patients After Treatment-A Single-Group Repeated-Measures   Trial. Diabetes Metab Syndr Obes. 2024 May 27;17:2165-2176. doi:   10.2147/DMSO.S458486. PMID: 38827164; PMCID: PMC11141577.

5.Han M, Cao X, Zhang J, Yang X, Zhang Y*, Liu Y*.   Association of Aldosterone, Renin, and Aldosterone to Renin Ratio with   Metabolic Profile in Primary Aldosteronism. Diabetes Metab Syndr Obes. 2024   May 18;17:2065-2074. doi: 10.2147/DMSO.S457243. PMID: 38778907; PMCID:   PMC11110821.

6.Li R, Wu B, Han M, Li M, Yang X, Zhang J, Zhang Y*, Liu Y*.   Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis. Diabetes Metab   Syndr Obes. 2024 Feb 7;17:661-673. doi: 10.2147/DMSO.S448547. PMID: 38343584;   PMCID: PMC10859102.

7.Xu M, Hao J, Qi Y, Wu B, Li R, Yang X, Zhang Y*, Liu Y*.   Causal effects of gut microbiota on diabetic neuropathy: a two-sample   Mendelian randomization study. Front Endocrinol (Lausanne). 2024 Aug   2;15:1388927. doi: 10.3389/fendo.2024.1388927. PMID: 39157679; PMCID:   PMC11329939.

8.Wang R, Chen K, Liu S, Ren R, Hou H, Zeng Q, Zhang Y*, Liu   Y*. Design, synthesis and biological evalsuation of novel oxazole derivatives   as potential hypoglycemic agents. Bioorg Med Chem. 2024 Nov 15;114:117961.   doi: 10.1016/j.bmc.2024.117961. Epub 2024 Oct 18. PMID: 39437535.

9.Ruifeng Wang, Xin Zhao, Hongbao Hou, Ke Chen, Shuihua Liu,   Ruyue Ren, Yunfeng Liu*, Yi Zhang*.    Cutting-Edge   FAK-targeting PROTACs: design, synthesis, and biological evalsuation. Journal of Chinese Pharmaceutical Sciences. 2024, Vol. 33:Issue (9):   767-782.DOI: 10.5246/jcps.2024.09.057

10.   Jiao JJ, Hu Y, Cui YJ, Tuo CM, Wang YX, Li XY, Zhang Y, Wu   MN. Anisomycin alleviates cognitive impairments and pathological features in   3xTg-AD mice. Neuropharmacology. 2024 Sep 18:110159. doi:   10.1016/j.neuropharm.2024.110159. Epub ahead of print. PMID: 39303856.

11.   Zhang X, Shi X, Zhang X, Zhang Y, Yu S, Zhang Y, Liu Y.   Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug   candidate based on TCGA database. Biomed Pharmacother. 2024 Sep;178:117293.   doi: 10.1016/j.biopha.2024.117293. Epub 2024 Aug 13. PMID: 39142251.

12.   Zhao X, Zeng Q, Yu S, Zhu X, Bin Hu, Deng L, Zhang Y, Liu   Y. GLP-1R mediates idebenone-reduced blood glucose in mice. Biomed   Pharmacother. 2024 Sep;178:117202. doi: 10.1016/j.biopha.2024.117202. Epub   2024 Jul 24. PMID: 39053424.

13.   Wang B, Zhu X, Yu S, Xue H, Deng L, Zhang Y, Zhang Y, Liu   Y. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease   by reducing hepatic steatosis and fibrosis in ob/ob mice. Biochem Biophys Res   Commun. 2024 Aug 30;722:150170. doi: 10.1016/j.bbrc.2024.150170. Epub 2024   May 23. PMID: 38797152.

14.   Li M, Zhang J, Yang G, Zhang J, Han M, Zhang Y, Liu Y.   Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in   patients with abnormal glucose metabolism: a meta-analysis of randomized   controlled trials. Eur J Clin Pharmacol. 2023 Jun;79(6):859-871. doi:   10.1007/s00228-023-03490-8. Epub 2023 Apr 25. PMID: 37097298.

15.   Zhang J, Li   MN, Yang GM, Hou XT, Yang D, Han MM, Zhang Y, Liu YF. Effects of water-sodium   balance and regulation of electrolytes associated with antidiabetic drugs.   Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5784-5794. doi:   10.26355/eurrev_202306_32817. PMID: 37401315.

16.   Li M, Liu   Z, Yang X, Zhang J, Han M, Zhang Y, Liu Y. The effect of sodium-glucose   cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1   diabetes assessed by continuous glucose monitoring: A systematic review and   meta-analysis. J Diabetes Complications. 2023 Dec;37(12):108632. doi:   10.1016/j.jdiacomp.2023.108632. Epub 2023 Oct 21. PMID: 37907042.

17.   Xue H, Xing   HJ, Wang B, Fu C, Zhang YS, Qiao X, Guo C, Zhang XL, Hu B, Zhao X, Deng LJ,   Zhu XC, Zhang Y, Liu YF. Cinchonine, a Potential Oral Small-Molecule   Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and   Ameliorates Non-Alcoholic Steatohepatitis. Drug Des Devel Ther. 2023 May   11;17:1417-1432. doi: 10.2147/DDDT.S404055. PMID: 37197367; PMCID:   PMC10184894.

18.   Li M, Zhang   J, Yang G, Zhang J, Han M, Zhang Y, Liu Y. Effects of Anterior Pituitary   Adenomas' Hormones on Glucose Metabolism and Its Clinical Implications.   Diabetes Metab Syndr Obes. 2023 Feb 13;16:409-424. doi: 10.2147/DMSO.S397445.   PMID: 36816815; PMCID: PMC9937076.

19.   Zhao   X, Deng L, Ren L, Yang H, Wang B, Zhu X, Zhang X, Guo C, Zhang Y, Liu Y.   VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in   rat pancreatic β cells. Exp Cell Res. 2023 Feb 15;423(2):113471. doi:   10.1016/j.yexcr.2023.113471. Epub 2023 Jan 13. PMID: 36642263.

20.   Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu. Effects of   the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for   Obesity and Diabetes. Diabetes Metabolic Syndrome and   Obesity-Targets and Therapy. 2022 Sep 25;15:2939-2950.doi:   10.2147/DMSO.S380577

21.   Xintong Hou, Dan Yang, Guimei Yang, Mengnan Li, Jian Zhang, Jiaxin Zhang, Yi Zhang, Yunfeng Liu. Therapeutic   potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2   diabetes.Frontiers in Endocrinology. 2022 Sep 20;13:984198.doi:   10.3389/fendo.2022.984198.

22.   Zhao X, Cui   L, Zhang Y, Guo C, Deng L, Wen Z, Lu Z, Shi X, Xing H, Liu Y, Zhang Y. Screening for Potential Therapeutic Agents for   Non-Small Cell Lung Cancer by Targeting Ferroptosis.Front Mol   Biosesci. 2022 Jul 14;9:917602. doi: 10.3389/fmolb.2022.917602. eCollection   2022.(2区)

23.   Tao Liu , Lijuan Cui, Huan Xue, Xiaohua Yang, Mengmeng Liu, Linping Zhi, Huanhuan Yang, Zhihong Liu, Min Zhang, Qing Guo, Peifeng He, Yunfeng Liu, Yi Zhang. Telmisartan   Potentiates Insulin Secretion via Ion Channels, Independent of the AT1   Receptor and PPARγ. Front Pharmacol . 2021 Sep 14;12:739637. doi:   10.3389/fphar.2021.739637. eCollection 2021.(2区)

24.   Xin   Zhao, Minghe Wang, Lijuan Cui, Chao   Fu, Zhihong Lu, Zhitong Wen, Huan Xue, Yunfeng Liu* and Yi Zhang*. GLP-1 Receptor Agonists: Beyond Its   Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug   23;12:721135. doi: 10.3389/fendo.2021.721135. eCollection 2021(2区)

25.   Zhihong Liu,Huanhuan   Yang,Linping Zhi,Huan Xue,Zhihong Lu,Yanli Zhao,Lijuan Cui,Tao Liu,Shouan Ren,Peifeng He,Yunfeng Liu   and Yi Zhang*. Sphingosine   1-phosphate stimulates insulin secretion and improves cell survival by   blocking voltage-dependent K + channels in β cells.Frontiers in Pharmacology,   2021. 12:683674.  doi: 10.3389/fphar.2021.683674(2区)

26.   Xiaohua   Yang, Min Zhang, Zhihong Lu, Linping Zhi, Huan Xue, Tao Liu, Mengmeng Liu,   Lijuan Cui, Zhihong Liu, Peifeng He, Yunfeng Liu* and Yi Zhang*. Novel Small   Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin   Secretion From Rat Islets. Frontiers in Pharmacology, 2021 Apr 29; 12:664802. doi:   10.3389/fphar.2021.664802. eCollection 2021.(2区)

27.   Lijuan Cui, Huan Xue, Zhitong Wen, Zhihong Lu, Yunfeng Liu, Yi Zhang*. Prognostic   roles of metabolic reprogramming-associated genes in patients with   hepatocellular carcinoma. Aging, 2020 Nov 12;12(21):22199-22219. doi: 10.18632/aging.104122. Epub 2020 Nov 12.(1区)

28.  T. BAI, H. YANG, H.   WANG, L. ZHI, T. LIU, L. CUI, W. Liu, Y. Wang, M. ZHANG, Y. Liu and Y. ZHANG*,   Inhibition of voltage-gated K+ channels mediates docosahexaenoic   acid-stimulated insulin secretion in rat pancreatic β-cells.[J] . Food &   Function, 2020, DOI:10.1039/D0FO01891K.(1区)

29.   Minmin Han,   Xiaoming Cao, Changjian Zhao, Luyang Yang, Nan Yin, Pengliang Shen, Jin Zhang,   Fei Gao, Yi Ren, Dong Liang, Jing Yang, Yi Zhang* and Yunfeng Liu*.   Assessment of Glycometabolism Impairment and Glucose Variability Using Flash   Glucose Monitoring System in Patients With Adrenal Diseases. Front Endocrinol   (Lausanne). 2020 September;11 doi: 10.3389/fendo.2020.544752(2区)

30.  Cui LJ, Bai T, Zhi LP,   Liu ZH, Liu T, Xue H, Yang HH, Yang XH, Zhang M, Niu YR, Liu YF, Zhang Y*.   Analysis of long noncoding RNA-associated competing endogenous RNA network in   glucagon-like peptide-1 receptor agonist-mediated protection in β cells.   World J Diabetes 2020; 11(9): 374-390

31.   Mengmeng Liu, Lele Ren, Xiangqin Zhong, Yaqin Ding, Tao Liu, Zhihong Liu, Xiaohua Yang, Lijuan Cui, Lijun Yang, Yanying Fan, Yunfeng Liu, Yi Zhang* . D2-Like   Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in   Rat Pancreatic β-Cells. Front Endocrinol (Lausanne). 2020 Apr   7;11:152. (通讯作者)2区,3.644

32.   Liu M, Yang X,   Bai T, Liu Z, Liu T, Wang Y, Cui L, Liu Y, Zhang Y*. PACAP stimulates insulin secretion by PAC1 receptor and   ion channels in β-cells. Cell Signal. 2019 Sep;61:48-56. (通讯作者)2区,3.388

33.   Liu Y,  Zhong X,   Ding Y, Ren L, Bai T, Liu M, Liu Z, Guo Y, Guo Q, Zhang Y, Yang J, Zhang Y*. Inhibition of voltage-dependent potassium   channels mediates cAMP-potentiated insulin secretion in rat pancreatic   β cells. Islets. 2017 Mar 4;9(2):11-18. (通讯作者). 4区,1.879

34.   Gao J, Bai T, Ren L, Ding Y, Zhong X, Wang H, Guo Y, Li J, Liu Y, Zhang Y*,  The PLC/PKC/Ras/MEK/Kv channel pathway is involved in uncarboxylated osteocalcin-regulated insulin secretion in rats.   Peptides. 2016   Dec;86:72-79. (通讯作者) 3区,2.659

35.   Zhang Y*, Ding Y, Zhong X, Guo Q, Wang H, Gao J, Bai T, Ren L, Guo Y, Jiao X, Liu Y. Geniposide acutely stimulates insulin secretion in pancreatic β-cells   by regulating GLP-1 receptor/cAMP signaling and ion channels. Mol Cell Endocrinol. 2016 Jul   15;430:89-96. (通讯作者)2区,3.693

36.   Gao J, Zhong X, Ding Y, Bai T, Wang H, Wu H, Liu Y, Yang J, Zhang Y*. Inhibition of   voltage-gated potassium channels mediates uncarboxylated   osteocalcin-regulated insulin secretion in rat pancreatic β cells. Eur J Pharmacol. 2016 Apr   15;777:41-8.(通讯作者)3区,3.17

37.   Zhang Y*, Wang   H, Guo Q, Li X, Gao J, Liu Y, Yang C, Niu L, Yang J. PI3K is involved   in P2Y receptor-regulated cAMP   /Epac/Kv channel signaling pathway in pancreatic β cells.   Biochem Biophys Res Commun. 2015 Oct 2;465(4):714-8. (通讯作者)3区,2.705

38.   Zhang Y*, Guo   Q, Li X, Gao J, Liu Y, Yang J, Li Q. P2Y purinergic receptor-regulated insulin   secretion is mediated by a cAMP/Epac/Kv channelpathway.   Biochem Biophys Res Commun. 2015 May 8;460(3):850-6. (通讯作者)3区,2.705

39.   Li X, Guo Q,   Gao J, Yang J, Zhang W, Liang Y, Wu D, Liu Y*, Weng J, Li Q, Zhang Y*. The   adenylyl cyclase inhibitor MDL-12,330A potentiates insulin secretion via   blockade of voltage-dependent K+ channels in pancreatic beta cells. PLOS one.   8(10):e77934.2013 (通讯作者)3区,2.776

40.   Liu Y*, Zhang   Y*, Zhu D*, Gaisano HY. VAMP8 Deletion Delays the Onset of   Streptozotocin-Induced Hyperglycemia. Can J Diabetes.   36 (2012) 251e256(*共同第一作者)4区,2.887

41.   Zhu D*,   Zhang Y*, Lam PP*, Dolai S*, Liu Y*, Cai EP, Choi D, Schroer SA, Kang Y,   Allister EM, Qin T, Wheeler MB, Wang CC, Hong WJ, Woo M, Gaisano HY.Dual Role of VAMP8 in Regulating Insulin Exocytosis and   Islet β Cell Growth. Cell Metab. 2012 Aug   8;16(2):238-49.   (*共同第一作者)top 1区,22.415

42.   Kang Y*,   Zhang Y*, Liang T*, Leung YM, Ng B, Xie H, Chang N, Chan J, Shyng SL,   Tsushima R, Gaisano HY. ATP modulates interaction of syntaxin-1A with   sulfonylurea receptor 1 to regulate pancreatic beta-cell KATP channels. J   Biol Chem. 2011 Feb 18;286(7):5876-83.(*共同第一作者)   2区,4.106

43.   Zhang Y,   Kang Y, Lam PPL, Chang N, Liu Y, Olkkonen VM, Gaisano HY. Cab45b, a Munc18b   Interacting-Partner, Regulates Exocytosis in Pancreatic Beta Cells. J Biol   Chem.  2009 Jul 31;284(31):20840-7,(第一作者)2区,4.106

44.   Zhang Y*, Liu   Y*, Qu J, Zhang N, Diao J, Strijbos P, Tsushima R, Robinson RB, Gaisano HY,   Wang Q, Wheeler MB. Functional Characterization of HCN Channels in   Rat Pancreatic β Cells. Journal   of Endocrinology 2009 Oct;203(1):45-53, (通讯作者) 2区,4.381

45.   Zhang Y, Zhang   N, Gyulkhandanyan AV, Xu E, Gaisano HY, Wheeler MB, Wang Q. Presence of   functional hyperpolarisation-activated cyclic nucleotide-gated channels in   clonal alpha cell lines and rat islet alpha cells. Diabetologia. 2008   Dec;51(12):2290-8.(第一作者)2区,7.113

46.  Xu E*, Kumar M*, Zhang   Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebian Y, Wheeler MB, Braun   M, Wang Q. Intra-islet insulin suppresses glucagon release via GABA-GABAA   receptor system. Cell Metabolism 2006; 3(1):47-58    (第二作者) top 1区,22.415

发明专利:

1.   日本专利:アニンマイシソ誘導体、アニンマイシソ及びその誘導体をG L P-1R作動薬としての使用方法,特許第7566378号;授权日期:2024.10.04

2.   一种GLP-1R激动剂。专利号:ZL 2023 1 0498208.X;授权日期:2025.02.11

3.   一种式(I)化合物制备镇痛药物中的用途。专利号:ZL 2022 1 0884726.0; 授权日期:2023.11.17  

4.   一种化合物在制备治疗阿尔兹海默症药物中的用途。专利号:ZL 2022 1 0884725.6;授权公告日:2024. 02. 02

5.   一种用于非酒精性脂肪肝病的化合物、组合物及其用途。专   利 号:ZL 2022 1 0878875.6 授权日期:2023年08月25日

6.   一种茴香霉素衍生物以及茴香霉素和其衍生物作为GLP-1R激动剂的用途。专利号:ZL 2021 1 0103556.3;授权日期:2023年05月30日

7.   一种小分子GLP-1R激动剂及其应用。专利号:ZL 2020 1 0498224.5。授权日期:2021.4.23

8.   国家发明专利:一种小分子GLP-1R激动剂及其应用。授权号:ZL 2020 1 0498224.5。授权日期:2021.4.23  (第一发明人)

9.   一种治疗乳腺癌的药物组合物。专 利 号:ZL 2023 1 0041357.3; 授权日期:2025年03月14日

10. 一种便于控制注射量的胰岛素注射笔。授权号:ZL   2020 2 2755790.8;授权日期:2021.12.28

获奖及个人荣誉

1.    第十一届全国大学生医学创新大赛暨2025“一带一路”国际医学创新竞赛铜奖

2.    第二届山西省博士后创新大赛金奖

3.    第十三届中国创新创业大赛山西赛区二等奖

4.    2023山西省留学人员创新创业大赛第2名

5.    2022深圳南山创新创业大赛生物医药行业赛第2名

6.    三晋英才科技创新领军人才

7.    山西省学术技术带头人

8.    山西省科技进步奖二等奖(2023,2021)

9.    山西省高等学校优秀成果科技进步二等奖

10. 山西省高等学校优秀青年学术带头人

11. 山西省科教兴晋突出贡献专家

研究生培养

培养的研究生多次获得国家奖学金